The Global Alzheimer’s Platform Foundation expands the Bio-Hermes-002 study, incorporating Sanofi and other industry leaders, to refine blood and digital biomarkers for more inclusive, earlier diagnosis of dementia…
The Global Alzheimer’s Platform Foundation expands the Bio-Hermes-002 study, incorporating Sanofi and other industry leaders, to refine blood and digital biomarkers for more inclusive, earlier diagnosis of dementia across diverse populations.
The Global Alzheimer’s Platform Foundation has said it is widening its Bio-Hermes-002 research programme with Sanofi joining as a new partner, in a study that is looking at whether blood-based and digital biomarkers can improve the identification of Alzheimer’s disease and related dementias. The observational project also incorporates MRI and PET imaging and is intended to reflect a broad mix of racial and ethnic groups, according to the foundation.
The initiative builds on earlier Bio-Hermes-001 work and adds to a growing list of commercial collaborators, including several diagnostics and biotechnology groups already involved in the project. GAP said the latest contribution will help expand the biomarker dataset being assembled through the study, which is designed to compare the performance of individual and combined measures against established signs of disease such as amyloid and tau in the brain.
The foundation said study data will be stored on the AD Workbench, a secure cloud platform run by the Gates Ventures Alzheimer’s Disease Data Initiative, allowing researchers to access and analyse information across different systems. Other organisations already tied to Bio-Hermes-002 include Roche, Siemens Healthineers and Spear Bio, while LifeArc has separately said it is backing the project with UK Dementia Research Institute support for work on a finger-prick style blood test and an enrolment target of 1,000 participants across the UK, the US and Canada.
The expanded collaboration comes as drugmakers and diagnostics companies increasingly focus on blood-based tests as a less invasive route to earlier dementia detection, although the field still needs stronger validation before such tools can be widely adopted in routine care. GAP has positioned the study as part of a broader effort to speed research and lower trial costs, but the practical value of the biomarkers will depend on whether the combined data can consistently improve diagnosis across diverse patient groups.
Source Reference Map
Inspired by headline at: [1]
Sources by paragraph: – Paragraph 1: [2] – Paragraph 2: [2], [6] – Paragraph 3: [4], [5], [6], [7] – Paragraph 4: [3], [5], [6]
Source: Noah Wire Services